We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$445M
AUM Growth
+$21.4M
Cap. Flow
-$1.93M
Cap. Flow %
-0.43%
Top 10 Hldgs %
46.96%
Holding
84
New
14
Increased
27
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$9.12M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.93M
4
VCYT icon
Veracyte
VCYT
+$5.3M
5
PCVX icon
Vaxcyte
PCVX
+$5.23M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$16.6M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.83M
3
CLDX icon
Celldex Therapeutics
CLDX
+$8.76M
4
NUVL
Nuvalent
NUVL
+$7.82M
5
URGN icon
UroGen Pharma
URGN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$38M 8.53%
371,441
-94,269
-20% -$7.82M
MRUS
2
DELISTED
Merus
MRUS
$31.7M 7.13%
635,439
+11,811
+2% +$617K
INSM icon
3
Insmed
INSM
$25.9B
$25.4M 5.7%
347,695
+207,695
+148% +$15.3M
RNAM
4
DELISTED
Avidity Biosciences
RNAM
$21.8M 4.91%
475,555
-42,179
-8% -$1.83M
ERAS icon
5
Erasca
ERAS
$6.31B
$19M 4.26%
6,946,488
-870,438
-11% -$2.45M
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$18.4M 4.12%
639,840
+14,753
+2% +$385K
VCYT icon
7
Veracyte
VCYT
$3.48B
$16M 3.6%
470,565
+188,317
+67% +$5.3M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.38B
$13.4M 3.01%
255,578
+70,916
+38% +$3.4M
COGT icon
9
Cogent Biosciences
COGT
$6.02B
$13.2M 2.96%
1,221,362
+15,148
+1% +$147K
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.2M 2.75%
167,110
-25,235
-13% -$1.9M
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$11.9M 2.67%
+744,592
New +$9.12M
URGN icon
12
UroGen Pharma
URGN
$2.13B
$11.4M 2.57%
901,129
-200,871
-18% -$2.98M
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.37B
$11.3M 2.53%
1,099,490
+23,678
+2% +$234K
PSTX
14
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10.5M 2.37%
3,687,548
+79,549
+2% +$246K
VRNA
15
DELISTED
Verona Pharma
VRNA
$10M 2.25%
348,866
+44,233
+15% +$1.09M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$31.7B
$9.84M 2.21%
35,774
-226
-0.6% -$58.8K
GERN icon
17
Geron
GERN
$970M
$8.18M 1.84%
1,801,561
+802,291
+80% +$3.65M
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.74B
$7.29M 1.64%
378,746
+8,746
+2% +$181K
PCVX icon
19
Vaxcyte
PCVX
$8.9B
$6.91M 1.55%
60,500
+58,000
+2,320% +$5.23M
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
$6.65M 1.49%
574,558
+13,675
+2% +$172K
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.34B
$6.6M 1.48%
+146,657
New +$5.93M
CCCC icon
22
C4 Therapeutics
CCCC
$474M
$6.54M 1.47%
1,147,891
-294,950
-20% -$1.78M
SRPT icon
23
Sarepta Therapeutics
SRPT
$2.2B
$6.4M 1.44%
51,245
+9,245
+22% +$1.28M
BDSX icon
24
Biodesix
BDSX
$283M
$6.34M 1.42%
178,055
+87,607
+97% +$3.01M
ELUT icon
25
Elutia
ELUT
$39M
$6.27M 1.41%
1,645,808
+42,228
+3% +$165K
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Silverarc Capital Management held 84 positions worth $445M, up 5.1% from $424M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Silverarc Capital Management's Q3 2024 filing shows 14 new, 27 increased, 18 reduced and 13 closed positions. Its largest new stake was Centessa Pharmaceuticals: 744,592 shares worth $11.9M. The largest sale was Morphic Holding, Inc. Common Stock, an estimated $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

  • Silverarc Capital Management's largest Q3 2024 buy was Centessa Pharmaceuticals: 744,592 shares worth $11.9M.
  • Silverarc Capital Management added most to Insmed in Q3 2024, an estimated $15.3M increase.
  • Silverarc Capital Management's biggest Q3 2024 reduction was Celldex Therapeutics, cutting an estimated $8.76M.
  • Silverarc Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $16.6M.
  • Silverarc Capital Management's ten largest holdings make up 47% of its $445M portfolio in Q3 2024.
  • Silverarc Capital Management opened 14 new positions and closed 13 in Q3 2024.
  • Silverarc Capital Management's portfolio value rose 5.1% quarter-over-quarter to $445M.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.